Metagenomi Therapeutics, Inc. (MGX) operating margin

Operating margin · fiscal 2025
-380.9%

Metagenomi Therapeutics, Inc. (MGX) had an operating margin of -380.9% in fiscal 2025 (the year ended December 31, 2025). That is 210.9 percentage points lower than the -170.0% of fiscal 2024. Figures as of 18 Nov 2026, 09:07 UTC, from Yahoo Finance.

Key facts

Operating margin, fiscal 2025
-380.9%
Change on fiscal 2024
−210.9 pts
Highest on record
-170.0%fiscal 2024
Lowest on record
-380.9%fiscal 2025
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Metagenomi Therapeutics, Inc. operating margin, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was -170.0% in fiscal 2024 and the lowest -380.9% in fiscal 2025. The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -175.4%.

Net margin was -348.5% in fiscal 2025.

History · 4 fiscal years

Operating margin by fiscal year

  • Operating margin
  • Net margin

Metagenomi Therapeutics, Inc. operating margin, year by year

Metagenomi Therapeutics, Inc. (MGX) operating margin by fiscal year
Fiscal yearOperating marginChangeYear endedNet margin
2025-380.9% 210.9 pts down-348.5%
2024-170.0% 5.4 pts up-149.3%
2023-175.4% 84.2 pts up-152.5%
2022-259.5%—-253.4%

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income.

How to read it

It shows how much of each unit of sales survives the cost of running the business — rising margins point to pricing power or scale, falling ones to pressure.

More on MGX

Metagenomi Therapeutics, Inc., figure by figure

Metagenomi Therapeutics, Inc. (MGX) overview: price, valuation and scorecard

Metagenomi Therapeutics, Inc. operating margin: questions and answers

What is Metagenomi Therapeutics, Inc.'s operating margin?

Metagenomi Therapeutics, Inc. (MGX) had an operating margin of -380.9% in fiscal 2025 (the year ended December 31, 2025). That is 210.9 percentage points lower than the -170.0% of fiscal 2024.

Is Metagenomi Therapeutics, Inc.'s operating margin high or low compared with its own history?

The fiscal 2025 figure is no higher than in any of the 3 earlier fiscal years on record, whose median is -175.4%.

What are the highest and lowest operating margin figures on record for Metagenomi Therapeutics, Inc.?

Across the 4 fiscal years on record (2022–2025), the highest was -170.0% in fiscal 2024 and the lowest -380.9% in fiscal 2025.

What are Metagenomi Therapeutics, Inc.'s gross and net margins?

Net margin was -348.5% in fiscal 2025.

How is Metagenomi Therapeutics, Inc.'s operating margin calculated?

Operating margin is operating income divided by revenue; gross margin does the same with gross profit, and net margin with net income. For Metagenomi Therapeutics, Inc. it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Metagenomi Therapeutics, Inc. (MGX) operating margin”, data as of 18 November 2026. https://funkfolio.com/stock/MGX/operating-margin

Underlying data: Yahoo Finance.